PTCT 241115 41.00C (PTCT241115C41000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PTCT241115C41000

Watchlist

2.15
0.000.00%

15min DelayClose Nov 4 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire16:30 ET
Earnings Preview: PTCT to Report Financial Results Post-market on November 07
Moomoo NewsNov 1 21:00 ET
PTC Therapeutics Resubmitted NDA for Translarna Accepted by FDA
Seeking AlphaOct 30 14:46 ET
PTC Therapeutics (NASDAQ:PTCT) Grows 8.1% This Week, Taking One-year Gains to 127%
Yahoo FinanceOct 30 09:02 ET
Express News | PTC Therapeutics Announces FDA Acceptance of Translarna™ Nda Resubmission
ReutersOct 30 07:00 ET
Express News | PTC Therapeutics Inc : Jefferies Raises Target Price to $51 From $43
ReutersOct 27 23:48 ET

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14 08:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Moomoo AI

Nov 18, 2023 08:43

PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.

PTC Therapeutics (NASDAQ:PTCT) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 68%